Cargando…

Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation

OBJECTIVE: To evaluate the effect of anticoagulation targets and intensity on bleeding events, thrombotic events, and transfusion requirements in patients with acute respiratory distress syndrome (ARDS) receiving venovenous extracorporeal membrane oxygenation (ECMO) and continuous-infusion heparin....

Descripción completa

Detalles Bibliográficos
Autores principales: Cercone, Jessica L., Kram, Shawn J., Trammel, Morgan A., Rackley, Craig R., Lee, Hui-Jie, Merchant, James, Kram, Bridgette L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101777/
https://www.ncbi.nlm.nih.gov/pubmed/35691853
http://dx.doi.org/10.1053/j.jvca.2022.05.012
_version_ 1784707170668904448
author Cercone, Jessica L.
Kram, Shawn J.
Trammel, Morgan A.
Rackley, Craig R.
Lee, Hui-Jie
Merchant, James
Kram, Bridgette L.
author_facet Cercone, Jessica L.
Kram, Shawn J.
Trammel, Morgan A.
Rackley, Craig R.
Lee, Hui-Jie
Merchant, James
Kram, Bridgette L.
author_sort Cercone, Jessica L.
collection PubMed
description OBJECTIVE: To evaluate the effect of anticoagulation targets and intensity on bleeding events, thrombotic events, and transfusion requirements in patients with acute respiratory distress syndrome (ARDS) receiving venovenous extracorporeal membrane oxygenation (ECMO) and continuous-infusion heparin. DESIGN: A retrospective cohort study. SETTING: At a single-center, large academic medical center. PARTICIPANTS: One hundred thirty-six critically ill patients. INTERVENTIONS: The following three therapeutic targets were implemented over time and evaluated: (1) no protocol (September 2013-August 2016): no standardized anticoagulation protocol or transfusion thresholds; (2) <50 seconds (September 2016-January 2018): standardized activated partial thromboplastin time (aPTT) goal of <50 seconds, maximum heparin infusion rate of 1,200 units/h, transfusion threshold of hemoglobin (Hgb) <8 g/dL; and (3) 40-to-50 seconds (February 2018-December 2019): aPTT goal of 40-to-50 sec, no maximum heparin infusion rate, transfusion threshold of Hgb <7 g/dL. MEASUREMENTS AND MAIN RESULTS: Continuous variables were compared using the Kruskal-Wallis test, and categorical variables were compared using Fisher exact tests. The primary endpoint, an incidence of at least 1 bleeding event, was highest in the no-protocol group though not statistically different among groups (39.3% v 26.7% v 34%, p = 0.5). Thrombotic complications were similar. The median units of packed red blood cells transfused were highest in the no-protocol group (3 v 2 v 0.5, p < 0.001). CONCLUSION: Anticoagulation protocols standardizing aPTT goals to <50 or 40-to-50 seconds may be a reasonable strategy for patients receiving venovenous ECMO for ARDS. More restrictive hemoglobin transfusion thresholds, in combination with lower aPTT targets, may be associated with a reduction in transfusion requirements.
format Online
Article
Text
id pubmed-9101777
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-91017772022-05-13 Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation Cercone, Jessica L. Kram, Shawn J. Trammel, Morgan A. Rackley, Craig R. Lee, Hui-Jie Merchant, James Kram, Bridgette L. J Cardiothorac Vasc Anesth Original Research OBJECTIVE: To evaluate the effect of anticoagulation targets and intensity on bleeding events, thrombotic events, and transfusion requirements in patients with acute respiratory distress syndrome (ARDS) receiving venovenous extracorporeal membrane oxygenation (ECMO) and continuous-infusion heparin. DESIGN: A retrospective cohort study. SETTING: At a single-center, large academic medical center. PARTICIPANTS: One hundred thirty-six critically ill patients. INTERVENTIONS: The following three therapeutic targets were implemented over time and evaluated: (1) no protocol (September 2013-August 2016): no standardized anticoagulation protocol or transfusion thresholds; (2) <50 seconds (September 2016-January 2018): standardized activated partial thromboplastin time (aPTT) goal of <50 seconds, maximum heparin infusion rate of 1,200 units/h, transfusion threshold of hemoglobin (Hgb) <8 g/dL; and (3) 40-to-50 seconds (February 2018-December 2019): aPTT goal of 40-to-50 sec, no maximum heparin infusion rate, transfusion threshold of Hgb <7 g/dL. MEASUREMENTS AND MAIN RESULTS: Continuous variables were compared using the Kruskal-Wallis test, and categorical variables were compared using Fisher exact tests. The primary endpoint, an incidence of at least 1 bleeding event, was highest in the no-protocol group though not statistically different among groups (39.3% v 26.7% v 34%, p = 0.5). Thrombotic complications were similar. The median units of packed red blood cells transfused were highest in the no-protocol group (3 v 2 v 0.5, p < 0.001). CONCLUSION: Anticoagulation protocols standardizing aPTT goals to <50 or 40-to-50 seconds may be a reasonable strategy for patients receiving venovenous ECMO for ARDS. More restrictive hemoglobin transfusion thresholds, in combination with lower aPTT targets, may be associated with a reduction in transfusion requirements. Elsevier Inc. 2022-09 2022-05-13 /pmc/articles/PMC9101777/ /pubmed/35691853 http://dx.doi.org/10.1053/j.jvca.2022.05.012 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Research
Cercone, Jessica L.
Kram, Shawn J.
Trammel, Morgan A.
Rackley, Craig R.
Lee, Hui-Jie
Merchant, James
Kram, Bridgette L.
Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation
title Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation
title_full Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation
title_fullStr Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation
title_full_unstemmed Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation
title_short Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation
title_sort effect of initial anticoagulation targets on bleeding and thrombotic complications for patients with acute respiratory distress syndrome receiving extracorporeal membrane oxygenation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101777/
https://www.ncbi.nlm.nih.gov/pubmed/35691853
http://dx.doi.org/10.1053/j.jvca.2022.05.012
work_keys_str_mv AT cerconejessical effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation
AT kramshawnj effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation
AT trammelmorgana effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation
AT rackleycraigr effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation
AT leehuijie effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation
AT merchantjames effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation
AT krambridgettel effectofinitialanticoagulationtargetsonbleedingandthromboticcomplicationsforpatientswithacuterespiratorydistresssyndromereceivingextracorporealmembraneoxygenation